Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2017-002116-14 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Children's Oncology Group | NETWORK |
Not provided
Not provided
Not provided
Not provided
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months for the first year, every 6 months for the second year, then yearly until the end of the study. Efficacy and safety will be assessed at study visits and as clinically indicated throughout the study. The study is expected to end in approximately 8 years after first patient first treatment (FPFT). A post-study long term follow-up safety will continue under a separate protocol per health authority guidelines.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single dose of CTL019 | Experimental | Based on the subject's weight one of two possible dose ranges will be prepared for the subject: Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight OR Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CTL019 | Biological | Based on the subject's weight, one of two possible dose ranges will be prepared for the subject: Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight OR Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells |
| Measure | Description | Time Frame |
|---|---|---|
| Disease Free Survival (DFS) rate without censoring for new anticancer therapy, including Stem Cell Transplantation (SCT) while in remission | DFS is defined as the time from the date of tisagenlecleucel infusion to the date of the first documented morphological relapse, occurrence of secondary malignancy or death due to any cause. | 5 years after tisagenlecleucel infusion |
| Overall Survival (OS) rate | OS is defined as the time from date of first tisagenlecleucel infusion to the date of death due to any reason. | 4 years after tisagenlecleucel |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of participants who are disease free without allogeneic stem cell transplant (SCT) | Minimal Residual Disease (MRD) negative remission (complete remission (CR) or Complete remission with incomplete blood count recovery CRi)) at Month 12 without SCT after tisagenlecleucel infusion. | 12 months after last infusion |
Not provided
Inclusion Criteria:
CD19 expressing B-cell Acute Lymphoblastic Leukemia
De novo NCI HR B-ALL who received first-line treatment and are MRD ≥ 0.01% at EOC. EOC bone marrow MRD will be collected prior to screening and will be assessed by multi-parameter flow cytometry using central laboratory analysis.
Age 1 to 25 years at the time of screening
Lansky (age < 16 years) or Karnofsky (age ≥ 16 years) performance status ≥ 60%
Adequate organ function during the screening period:
A. Renal function based on age/gender B. ALT ≤ 5 times ULN for age C. AST ≤ 5 times ULN for age D. Total bilirubin < 2 mg/dL (for Gilbert's Syndrome subjects total bilirubin < 4 mg/dL)
E. Adequate pulmonary function defined as:
Prior induction and consolidation chemotherapy allowed: 1st line subjects: ≤ 3 blocks of standard chemotherapy for first-line B-ALL, defined as 4-drug induction, Berlin-Frankfurt-Münster (BFM) consolidation or Phase 1b, and interim maintenance with high-dose methotrexate.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion may apply.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children s Hospital of Alabama | Birmingham | Alabama | 35233 | United States | ||
| Phoenix Childrens Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41671463 | Derived | Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. | |
| 32589970 | Derived | Seftel MD. Hyper-CVAD: a regimen for all seasons. Lancet Haematol. 2020 Jul;7(7):e501-e502. doi: 10.1016/S2352-3026(20)30179-4. No abstract available. |
Not provided
Not provided
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DFS rate with censoring for new anticancer therapy, including SCT, while in remission |
Assessing the effect of tisagenlecleucel on DFS if new anticancer therapy is not available. |
| 5 years |
| Percentage of participants achieving MRD negative CR or CRi at Month 3 | Assessing the percentage of participants who achieved MRD negative complete response (CR) or Complete remission with incomplete blood count recovery (CRi) status as determined by central laboratory using multi-parameter flow cytometry. | 3 months after the tisagenlecleucel infusion. |
| Pediatric Quality of Life (PedsQL) | Patient reported outcome to assess quality of life in patients aged 8 and above. The 23 items PedQL (Pediatrics Quality of Life Inventory) measure core dimensions of health as delineated by the World Health Organization, as well as role (school) functioning. Items measured include 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items). Each item is measured on a 5 point Likert scale with 0 indicating "never" and 4 indicating "almost always". The Likert scores are reversed scored and linearly transform to a 0-100 scale with 0=100, 1-75, 2=50, 5=25, and 4=0. A higher score indicates better health-related quality of life (HRQoL). | 5 years |
| European Quality of Life 5 dimensions (EQ-5D-3L & EQ-5D-Y)) | Patient reported outcome to assess health status in patients aged 8 and above. The EQ-5D (European Quality of Life -5 Dimensions) measures a wide range of health conditions and treatments; it is composed of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (EQ-visual analogue scale [EQ-VAS]) that records the patient's self-rated overall health state. Respondents rate each of these 5 dimensions from "no problem", "some problem," or "extreme problem". The EQ-VAS records the respondents' self-related health on a vertical, visual analogue scale. The range for EQ-VAS is from 0 (=the worst health you can imagine) to 100 (=the best health you can imagine). | 5 years |
| Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Detection test | Speed of performance (mean of the log10 transformed reaction times for correct responses) | 5 years |
| Impact of tisagenlecleucel on cognitive functioning usingComputerized neurocognitive assessment: Identification test | This test measures the speed of performance (mean of the log10 transformed reaction times for correct responses) | 5 years |
| Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: Groton Maze Learning test | This test looks at the total number of errors made in attempting to learn the hidden pathways during a single session. | 5 years |
| Impact of tisagenlecleucel on cognitive functioning using Computerized neurocognitive assessment: One Back test | This test measures the accuracy of performance (arcsine transformation of the square root of the percentage of correct responses). The test also measures the speed of performance (mean of the log10 transformed reaction times for correct responses). | 5 years |
| Impact of tisagenlecleucel on cognitive functioning usingComputerized neurocognitive assessment: One card learning test | This test measures the accuracy of performance (arcsine transformation of the square root of the proportion of correct responses). | 5 years |
| Percentage of participants with pre-existing antibodies | Prevalence of immunogenicity | 8 years |
| Percentage of participants with anti-m CAR19 antibodies post infusion with tisagenlecleucel and % of patients without measureable anti-mCAR19 antibodies | Incidence of immunogenicity | 8 years |
| Percentage of patients that have measureable anti-mCAR19 antibodies above patient specific cut-point (reported as a %) pre and post tisagenlecleucel infusion categorized by Day 28 response | Impact of immunogenicity on clinical response | 8 years |
| tisagenlecleucel transgene concentration | Transgene concentration as detected by qPCR in target tissue | 8 years |
| Expression of tisagenlecleucel | Summary of tisagenlecleucel CAR-positive viable T cells measured by flow cytometry in target tissue | 8 years |
| Persistence of CAR (reported as copies/ug) categorized by the time to B-cell recovery (recovery < 3 months, >3 months to < 6months, > 6 months) | Relationship between B-cell recovery and transgene levels | 8 years |
| Cmax; cellular kinetic parameter of tisagenlecleucel | The maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration (% or copies/μg) | 8 years |
| Tmax; cellular kinetic parameter of tisagenlecleucel | The time to reach maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days) | 8 years |
| AUC0-29d and 84d; cellular kinetic parameter of tisagenlecleucel | The AUC from time zero to day 29 and 84 or other disease assessment days, in peripheral blood (% or copies/μg x days ) | 8 years |
| AUC0-Tmax; cellular kinetic parameter of tisagenlecleucel | The AUC from time zero to Tmax in peripheral blood (% or copies/μg x days) | 8 years |
| T1/2; cellular kinetic parameter of tisagenlecleucel | The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood | 8 years |
| Clast; cellular kinetic parameter of tisagenlecleucel | The last observed quantifiable concentration in peripheral blood (% or copies/μg) | 8 years |
| Tlast; cellular kinetic parameter of tisagenlecleucel | The time of last observed quantifiable concentration in peripheral blood (days) | 8 years |
| Impact of tisagenlecleucel dose on day 29 response | Clinical response summarized by quartile of administered doses | 8 years |
| AUC 0 - 29d; cellular kinetic parameter of tisagenlecleucel | Impact of tisagenlecleucel exposure on day 29 response; The AUC from time zero to day 29 in peripheral blood (% or copies/μg x days ) | Day 29 |
| Cmax: cellular kinetic parameter of tisagenlecleucel | Impact of tisagenlecleucel exposure on day 29 response; The maximum (peak) observed in peripheral blood or other body fluid drug concentration after single dose administration (% or copies/μg) | Day 29 |
| Tmax: cellular kinetic parameter of tisagenlecleucel | Impact of tisagenlecleucel exposure on day 29 response; The time to reach maximum (peak) peripheral blood or other body fluid drug concentration after single dose administration (days) | Day 29 |
| T1/2: cellular kinetic parameter of tisagenlecleucel | Impact of tisagenlecleucel exposure on day 29 response; The half-life associated with the elimination phase slope of a semi logarithmic concentration-time curve (days) in peripheral blood | Day 29 |
| Phoenix |
| Arizona |
| 85016 |
| United States |
| City of Hope National Medical | Duarte | California | 91010 | United States |
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | United States |
| Mattel Childrens Hospital UCLA | Los Angeles | California | 90095 | United States |
| Childrens Hospital of Orange County | Orange | California | 92868-3874 | United States |
| Rady Children s Hospital | San Diego | California | 92123 | United States |
| UCSF Medical Center | San Francisco | California | 94143 | United States |
| Stanford University Medical Center | Stanford | California | 94304 | United States |
| Childrens Hospital Colorado | Aurora | Colorado | 80045 | United States |
| Childrens National Hospital | Washington D.C. | District of Columbia | 20010 | United States |
| Johns Hopkins All Childrens | St. Petersburg | Florida | 33701 | United States |
| Childrens Healthcare of Atlanta | Atlanta | Georgia | 30342 | United States |
| Indiana University | Indianapolis | Indiana | 46202-5225 | United States |
| Johns Hopkins Oncology Center | Baltimore | Maryland | 21231 | United States |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States |
| Children s Mercy Hospital | Kansas City | Missouri | 64108 | United States |
| Hackensack Uni Medical Center | Hackensack | New Jersey | 07601 | United States |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | United States |
| Memorial Sloan Kettering Cancer Ctr | New York | New York | 10065 | United States |
| Columbia University Medical Center | New York | New York | 110032 | United States |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| Cinn Children Hosp Medical Center | Cincinnati | Ohio | 45229-3039 | United States |
| Oregon Health and Science University | Portland | Oregon | 97239-3098 | United States |
| The Childrens Hosp of Philadelphia | Philadelphia | Pennsylvania | 19104 | United States |
| Univ of Texas Southwest Med Center | Dallas | Texas | 75390-9034 | United States |
| Texas Childrens Cancer and Hematology Center | Houston | Texas | 77030 | United States |
| Methodist Childrens Hospital | San Antonio | Texas | 78229 | United States |
| University of Utah Clinical Trials Office | Salt Lake City | Utah | 84108 | United States |
| Childrens Hospital of Wisconsin | Milwaukee | Wisconsin | 53226 | United States |
| Novartis Investigative Site | Ghent | 9000 | Belgium |
| Novartis Investigative Site | Calgary | Alberta | T3B 6A8 | Canada |
| Novartis Investigative Site | Toronto | Ontario | M5G 1X8 | Canada |
| Novartis Investigative Site | Montreal | Quebec | H3T 1C5 | Canada |
| Novartis Investigative Site | Copenhagen | DK-2100 | Denmark |
| Novartis Investigative Site | Paris | 75019 | France |
| Novartis Investigative Site | Roma | RM | 00165 | Italy |
| Novartis Investigative Site | Utrecht | 3584 CS | Netherlands |
| Novartis Investigative Site | Oslo | 0424 | Norway |
| Novartis Investigative Site | Esplugues | Barcelona | 08950 | Spain |
| Novartis Investigative Site | Gothenburg | SE 416 85 | Sweden |
| Novartis Investigative Site | London | NW1 2BU | United Kingdom |
| Novartis Investigative Site | London | WC1N 3JH | United Kingdom |
| ID | Term |
|---|---|
| D002051 | Burkitt Lymphoma |
| D018365 | Neoplasm, Residual |
| ID | Term |
|---|---|
| D020031 | Epstein-Barr Virus Infections |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
| D014412 | Tumor Virus Infections |
| D016393 | Lymphoma, B-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000626284 | tisagenlecleucel |
Not provided
Not provided
Not provided